Testing inside the fab or packaging house can determine whether a chip or package meets all the functional requirements at time zero, but how that chip behaves in the field during its lifetime and ...

Results from the PATHFINDER 2 trial of Grail's blood test for multiple cancers have shown greater efficacy and a lower rate of false alarms than in an earlier trial of the technology. The Galleri ...

High-Grade Gold Rock Chips From TibooburraHIGHLIGHTS Rock chip results from a recently completed reconnaissance program at ...

Grail is on a mission to have its cancer blood test become a core part of U.S. screening for a range of tumors. Now, it’s detailing its latest data as it heads to the FDA. Back in June, Grail revealed ...

Simply sign up to the Artificial intelligence myFT Digest -- delivered directly to your inbox. Data centre start-up Crusoe has raised $1.4bn, more than tripling its valuation to over $10bn in one year ...

Canada’s economic growth in the third quarter could fall short of the Bank of Canada’s forecast given the latest contracting manufacturing sales data, says one economist. Manufacturing sales ...

Shares of Grail have quintupled this year to nearly $90, as investors waited for news about the Pathfinder 2 study of its cancer-detecting blood test. Management hinted this summer the numbers were ...

The country’s medicines regulator has privately raised serious concerns about the reliability of sun protection testing from a popular British laboratory, warning its data looks too perfect and lacks ...

New Data Show Early Use of Delve Bio’s Metagenomic Testing Can Reduce Need for Conventional Tests and Overall Length of Stay for Patients with Meningitis/Encephalitis Data presented at IDWeek 2025 ...

・The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus bacteremia, with no relapses reported. ・H.C. Wainwright reiterated a ‘Buy’ ...